American Century Companies Inc. acquired a new stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) in the 1st quarter, according to its most recent filing with the SEC. The fund acquired 11,908 shares of the company's stock, valued at approximately $195,000.
Other institutional investors and hedge funds have also modified their holdings of the company. GF Fund Management CO. LTD. acquired a new position in shares of IDEAYA Biosciences in the 4th quarter valued at approximately $47,000. CWM LLC grew its position in shares of IDEAYA Biosciences by 325.7% in the 1st quarter. CWM LLC now owns 2,371 shares of the company's stock valued at $39,000 after purchasing an additional 1,814 shares during the period. PNC Financial Services Group Inc. grew its position in shares of IDEAYA Biosciences by 180.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 2,404 shares of the company's stock valued at $39,000 after purchasing an additional 1,546 shares during the period. Signaturefd LLC boosted its position in IDEAYA Biosciences by 374.8% during the 1st quarter. Signaturefd LLC now owns 2,877 shares of the company's stock worth $47,000 after acquiring an additional 2,271 shares during the last quarter. Finally, Exchange Traded Concepts LLC boosted its position in IDEAYA Biosciences by 46.4% during the 1st quarter. Exchange Traded Concepts LLC now owns 6,659 shares of the company's stock worth $109,000 after acquiring an additional 2,112 shares during the last quarter. 98.29% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of equities analysts have weighed in on the company. Wells Fargo & Company assumed coverage on IDEAYA Biosciences in a research report on Thursday, June 26th. They set an "overweight" rating and a $44.00 price target for the company. Stephens reaffirmed an "overweight" rating and set a $45.00 price target on shares of IDEAYA Biosciences in a research report on Tuesday. Oppenheimer set a $36.00 price target on IDEAYA Biosciences and gave the stock an "outperform" rating in a research report on Monday. Citigroup reaffirmed a "buy" rating on shares of IDEAYA Biosciences in a research report on Tuesday. Finally, Citizens Jmp assumed coverage on IDEAYA Biosciences in a research report on Thursday, September 4th. They set a "mkt outperform" rating and a $41.00 price target for the company. Thirteen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, IDEAYA Biosciences presently has an average rating of "Moderate Buy" and a consensus target price of $42.85.
View Our Latest Report on IDYA
IDEAYA Biosciences Trading Down 1.3%
Shares of IDEAYA Biosciences stock traded down $0.32 on Friday, reaching $24.61. 1,047,343 shares of the company were exchanged, compared to its average volume of 1,194,808. IDEAYA Biosciences, Inc. has a one year low of $13.45 and a one year high of $37.80. The company has a market capitalization of $2.16 billion, a price-to-earnings ratio of -6.49 and a beta of 0.12. The company has a 50-day moving average of $23.94 and a 200 day moving average of $20.75.
IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.03). The firm had revenue of $6.00 million during the quarter, compared to the consensus estimate of $3.48 million. During the same quarter in the prior year, the company posted ($0.68) EPS. The firm's quarterly revenue was up NaN% on a year-over-year basis. Analysts predict that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current year.
About IDEAYA Biosciences
(
Free Report)
IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.
See Also
Before you consider IDEAYA Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEAYA Biosciences wasn't on the list.
While IDEAYA Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
